A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

June 16, 2017

Study Completion Date

June 16, 2017

Conditions
Healthy
Interventions
DRUG

JNJ-64041575

Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.

DRUG

Probenecid

One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).

Trial Locations (1)

10117

Charité Research Organisation GmbH, Berlin

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY

NCT03105986 - A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults | Biotech Hunter | Biotech Hunter